This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Safety, clinical tolerability and immunogenicity o...
Clinical trial

Safety, clinical tolerability and immunogenicity of increasing doses of gpASIT+TM administered subcutaneously to hay fever patients. A Phase IIa dose-escalation study.

Read time: 1 mins
Last updated:4th Feb 2013
The primary objective of this clinical trial in patients suffering from hay fever is the assessment of the safety and clinical tolerability of increasing doses of gpASIT+TM when administered by subcutaneous injections, in order to determine the maximal tolerated dose.
Category Value
Study start date 2013-02-04

View full details